Financials
| Full year results and review of strategic options | Apr. 25, 2024 |
| Interim Results | Sep. 20, 2023 |
| Audited results for year ended 31 December 2022 | Apr. 13, 2023 |
| Year End Trading Update | Dec. 22, 2022 |
| Interim results for six months ended 30 June 2022 | Sep. 08, 2022 |
| Audited results for year ended 31 December 2021 | Apr. 12, 2022 |
| Clinical and commercial opportunity of NTCD-M3 | Jan. 24, 2022 |
Proxies
| Result of Annual General Meeting | Jun. 12, 2024 |
| 2024 Annual General Meeting and Statement | Jun. 12, 2024 |
| Posting of Annual Report and Notice of AGM | May. 09, 2024 |
| Result of Annual General Meeting | May. 25, 2023 |
| Posting of Annual Report and Notice of AGM | Apr. 26, 2023 |
| Result of Annual General Meeting & Strategy Update | May. 27, 2022 |
| Posting of Annual Report and Notice of AGM | Apr. 27, 2022 |
Ownership Update
| Director/PDMR Shareholding | Aug. 05, 2024 |
| Grant of Share Options | Oct. 20, 2023 |
| Director/PDMR Shareholding | Oct. 19, 2023 |
| Director/PDMR Shareholding | Oct. 04, 2023 |
| Director/PDMR Shareholding | May. 26, 2023 |
| Director Dealing | May. 26, 2023 |
| Grant of Share Options | May. 12, 2023 |
Announcements
| FDA grants XF-73 Dermal QIPD for burn wound | Aug. 28, 2024 |
| Presentation at ESCMID on XF-73 Nasal Gel | Aug. 20, 2024 |
| Exploration of XF drug potential for CF | Aug. 14, 2024 |
| Last Day of Dealings on AIM | Aug. 12, 2024 |
| XF-73 prevents bacterial invasion of bloodstream | Aug. 05, 2024 |
| Result of GM and Cancellation of Trading on AIM | Jul. 31, 2024 |
| Treatment of XF-73 Nasal reduces antibiotic use | Jul. 22, 2024 |